Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer

By Lucarelli Giuseppe   Ditonno Pasquale   Bettocchi Carlo   Spilotros Marco   Rutigliano Monica   Vavallo Antonio   Galleggiante Vanessa   Fanelli Margherita   Larocca Angela Maria Vittoria   Germinario Cinzia Annatea   Maiorano Eugenio   Selvaggi Francesco Paolo   Battaglia Michele  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 899-907

Future Medicine

Access to resources Recommend Favorite

Molecular mechanisms of castration-resistant prostate cancer progression

By Dutt Smitha S   Gao Allen C  

Future Oncology, Vol. 5, Iss. 9, 2009-11 ,pp. : 1403-1413

Future Medicine

Access to resources Recommend Favorite

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex   Mohammed Aza   Miller Marek   Kunkler Roger  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1040-1045

Bentham Science Publishers

Access to resources Recommend Favorite

New Therapeutic Strategies for Castration-Resistant Prostate Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, Iss. 3, 2011-09 ,pp. : 373-383

Bentham Science Publishers

Access to resources Recommend Favorite